Tinlarebant (LBS-008)

Stargardt disease type 1

Manufacturer: Belite Bio
Regulatory submission: NDA submitted June 2026
Launch: Anticipated in March 2027
Last updated: September 19, 2026

Section

Product information and disease description Product description Product information

Indication

1 evidence topic · 1 source

Investigational indication: orphan designation

“Treatment of Stargardt disease” (opens the source at this quote in a new tab)